



Lamisil® (terbinafine) – New Contraindication

- The [FDA approved](#) a new *Contraindication* for [Lamisil \(terbinafine\)](#) oral tablets regarding use in patients with chronic or active liver disease.
 - Before prescribing Lamisil, liver function tests should be performed because hepatotoxicity may occur in patients with and without preexisting liver disease.
 - Cases of liver failure, some leading to liver transplant or death, have occurred with the use of Lamisil.
- Lamisil tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium).
- Other warnings and precautions of Lamisil include hepatotoxicity, taste disturbance including loss of taste, smell disturbance including loss of smell, depressive symptoms, hematologic effects, serious skin/hypersensitivity reactions, lupus erythematosus, and laboratory monitoring.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.